Profile data is unavailable for this security.
About the company
FitLife Brands, Inc. is a developer and marketer proprietary nutritional supplements and wellness products for health-conscious consumers. It markets approximately 300 different products primarily online, through domestic and international GNC franchise locations as well as through more than 17,000 additional domestic retail locations. It offers NDS Nutrition, PMD Sports, SirenLabs, Core Active, Nutrology, and Metis Nutrition (together, NDS Products); iSatori, BioGenetic Laboratories, and Energize (together, the iSatori Products); Dr. Tobias, All Natural Advice, and Maritime Naturals (together, the MRC Products) and MusclePharm. Its NDS brand includes premium weight loss, sports nutrition, and general health products. Its PMD brand includes premium sports nutrition products. Its Nutrology brand included sports nutrition and general wellness products with an emphasis on natural, vegan, and organic ingredients. Its SirenLabs brand includes weight loss and sports nutrition products.
- Revenue in USD (TTM)58.51m
- Net income in USD7.30m
- Incorporated2005
- Employees37.00
- LocationFitLife Brands Inc5214 S. 136Th StreetOMAHA 68137United StatesUSA
- Phone+1 (402) 884-1894
- Websitehttps://fitlifebrands.com/
More ▼
Mergers & acquisitions
| Acquired company | FTLF:NAQ since announced | Transaction value |
|---|---|---|
| MusclePharm Corp | 100.85% | 28.51m |
Data delayed at least 15 minutes, as of May 31 2024 21:00 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Syros Pharmaceuticals Inc | 6.98m | -144.49m | 133.64m | 68.00 | -- | 8.88 | -- | 19.14 | -5.01 | -5.01 | 0.2244 | 0.5633 | 0.0411 | -- | -- | 102,661.80 | -84.98 | -54.44 | -103.51 | -64.32 | -- | -- | -2,069.80 | -772.82 | -- | -- | 0.7332 | -- | -33.23 | 37.12 | -73.87 | -- | -27.78 | -- |
| CytomX Therapeutics Inc | 119.18m | 16.53m | 136.36m | 120.00 | 8.85 | -- | 7.34 | 1.14 | 0.1978 | 0.1978 | 1.53 | -0.4649 | 0.5684 | -- | 16.71 | 993,150.00 | 7.89 | -21.53 | 26.77 | -32.32 | -- | -- | 13.87 | -100.38 | -- | -- | -- | -- | 90.38 | 11.21 | 99.43 | -- | -26.01 | -- |
| Global Pharmatech Inc. | 3.18m | -2.24m | 138.32m | 217.00 | -- | 1.02 | -- | 43.51 | -0.0964 | -0.0964 | 0.1367 | 0.3428 | 0.2292 | 1.59 | 3.57 | 14,649.77 | -16.44 | -- | -22.55 | -- | 46.21 | -- | -71.75 | -- | 1.62 | -9.87 | 0.2223 | -- | 32.43 | -- | -142.03 | -- | -- | -- |
| FitLife Brands Inc | 58.51m | 7.30m | 140.57m | 37.00 | 20.67 | 4.78 | 18.97 | 2.40 | 1.48 | 1.48 | 11.87 | 6.39 | 1.20 | 3.87 | 27.13 | 1,581,351.00 | 15.03 | 26.40 | 19.37 | 33.92 | 41.55 | 42.09 | 12.48 | 17.65 | 0.5177 | 12.32 | 0.3582 | -- | 82.97 | 25.28 | 19.58 | 67.31 | -- | -- |
| I-Mab ADR | 3.82m | -202.67m | 140.74m | 220.00 | -- | 0.591 | -- | 36.82 | -2.44 | -2.44 | 0.0459 | 2.94 | 0.0083 | -- | -- | 17,375.28 | -43.84 | -35.99 | -53.14 | -42.08 | 100.00 | -- | -5,302.03 | -496.71 | -- | -42.63 | 0.0171 | -- | 112.48 | -12.46 | 41.54 | -- | -4.66 | -- |
| Rapt Therapeutics Inc | 0.00 | -118.05m | 140.94m | 126.00 | -- | 1.08 | -- | -- | -3.07 | -3.07 | 0.00 | 3.76 | 0.00 | -- | -- | 0.00 | -58.42 | -46.30 | -65.33 | -49.97 | -- | -- | -- | -3,522.72 | -- | -- | 0.00 | -- | -100.00 | -- | -39.31 | -- | -20.31 | -- |
| Veru Inc | 13.48m | -35.82m | 141.47m | 189.00 | -- | 3.13 | -- | 10.50 | -0.3465 | -0.3465 | 0.1267 | 0.3089 | 0.1898 | 1.42 | 3.86 | 71,318.68 | -50.43 | -42.91 | -76.84 | -54.41 | 34.13 | 72.41 | -265.74 | -104.96 | 4.22 | -- | 0.177 | -- | -58.59 | 0.5394 | -10.84 | -- | 67.39 | -- |
| Repare Therapeutics Inc | 97.86m | -45.69m | 142.19m | 179.00 | -- | 0.6077 | -- | 1.45 | -1.10 | -1.10 | 2.30 | 5.51 | 0.3265 | -- | 9.22 | 546,698.30 | -15.25 | -23.40 | -18.73 | -26.37 | -- | -- | -46.69 | -162.76 | -- | -- | 0.00 | -- | -61.21 | -- | -222.91 | -- | 27.16 | -- |
| Cardiff Oncology Inc | 610.00k | -40.25m | 142.22m | 31.00 | -- | 2.33 | -- | 233.15 | -0.901 | -0.901 | 0.0137 | 1.36 | 0.0068 | -- | 1.14 | 19,677.42 | -44.55 | -31.24 | -50.10 | -33.56 | -- | -- | -6,594.92 | -7,819.23 | -- | -- | 0.00 | -- | 26.42 | 5.22 | -7.07 | -- | 157.91 | -- |
| Vaxart Inc | 8.89m | -81.74m | 143.93m | 109.00 | -- | 2.58 | -- | 16.20 | -0.5431 | -0.5431 | 0.059 | 0.3155 | 0.0813 | -- | 21.67 | 81,513.76 | -74.81 | -49.60 | -86.63 | -54.86 | -- | -- | -920.00 | -1,398.00 | -- | -- | 0.0705 | -- | 6,796.26 | 12.15 | 23.47 | -- | 21.49 | -- |
| Scpharmaceuticals Inc | 17.63m | -57.71m | 144.58m | 135.00 | -- | 5.89 | -- | 8.20 | -1.49 | -1.49 | 0.4545 | 0.6814 | 0.1713 | 0.7566 | 4.02 | 130,607.40 | -56.07 | -38.23 | -62.13 | -42.31 | 71.69 | -- | -327.29 | -1,360.16 | 5.44 | -16.60 | 0.6159 | -- | -- | -- | -48.79 | -- | -- | -- |
| Seres Therapeutics Inc | 126.85m | -82.68m | 147.51m | 233.00 | -- | -- | -- | 1.16 | -0.6062 | -0.6062 | 0.9495 | -0.3945 | 0.4149 | -- | -- | 544,407.80 | -27.04 | -41.51 | -36.82 | -54.13 | -- | -- | -65.18 | -170.14 | 1.25 | -9.21 | 2.41 | -- | 1,672.24 | 34.91 | 54.54 | -- | 32.72 | -- |
| Regulus Therapeutics Inc | 0.00 | -31.37m | 147.95m | 28.00 | -- | 1.38 | -- | -- | -1.46 | -1.46 | 0.00 | 1.64 | 0.00 | -- | -- | 0.00 | -41.50 | -53.74 | -45.91 | -76.96 | -- | -- | -- | -715.58 | -- | -- | 0.005 | -- | -- | -- | -6.05 | -- | 94.54 | -- |
| ProQR Therapeutics NV | 14.61m | -29.08m | 148.88m | 157.00 | -- | 4.09 | -- | 10.19 | -0.3581 | -0.3581 | 0.18 | 0.4477 | 0.0957 | -- | -- | 93,058.66 | -18.83 | -35.51 | -23.01 | -40.51 | -- | -- | -196.75 | -926.31 | -- | -- | 0.3557 | -- | 118.51 | 10.58 | 56.35 | -- | 34.45 | -- |
| Mediwound Ltd | 19.85m | -12.75m | 148.91m | 100.00 | -- | 6.56 | -- | 7.50 | -1.38 | -1.38 | 2.15 | 2.44 | 0.303 | 5.64 | 5.07 | 198,510.00 | -19.46 | -24.48 | -25.65 | -32.92 | 16.92 | 43.27 | -64.24 | -38.43 | 1.83 | -- | 0.218 | -- | -29.48 | 40.60 | 65.73 | -- | 64.66 | -- |
Data as of May 31 2024. Currency figures normalised to FitLife Brands Inc's reporting currency: US Dollar USD
47.26%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Sudbury Capital Management LLCas of 28 Dec 2023 | 2.07m | 44.98% |
| Horizon Kinetics Asset Management LLCas of 31 Mar 2024 | 77.23k | 1.68% |
| Millennium Management LLCas of 31 Mar 2024 | 12.16k | 0.26% |
| Geode Capital Management LLCas of 31 Mar 2024 | 11.49k | 0.25% |
| Osaic Wealth, Inc. (Investment Management)as of 31 Mar 2024 | 1.40k | 0.03% |
| UBS Securities LLCas of 31 Mar 2024 | 1.28k | 0.03% |
| Harbor Investment Advisory LLCas of 31 Mar 2024 | 900.00 | 0.02% |
| Tower Research Capital LLCas of 31 Mar 2024 | 605.00 | 0.01% |
| Wells Fargo Bank, NA (Private Banking)as of 31 Mar 2024 | 14.00 | 0.00% |
| JPMorgan Securities LLC (Investment Management)as of 31 Mar 2024 | 4.00 | 0.00% |
More ▼
Data from 31 Mar 2024 - 19 Apr 2024Source: FactSet Research Systems Inc.
